Bagsværd, Denmark, 06 May 2024 – This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.
Please find below a statement of such trading in shares issued by Novo Nordisk.
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name of the Board member/Executive/Associated Person
Novo Holdings A/S, associated to Kasim Kutay
2
Reason for the notification
a)
Position/status
Member of the Board of Directors
b)
Initial notification/Amendment
Initial notification
3
Details of the issuer
a)
Name
Novo Nordisk A&S
b)
LEI
549300DAQ1CVT6CXN342
4
Details of the transaction(s)
a)
Description of the financial instrument, type of instrument,
Identification code
Shares
Novo Nordisk B DK0062498333
b)
Nature of the transaction
Sale of shares
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| DKK 860.02 | 6,311,250 shares |
d)
Aggregated information
- Aggregated volume
- Price
6,311,250 shares
DKK 5,427,801,225.00
e)
Date of the transaction
2024-05-06
f)
Place of the transaction
Outside a trading venue
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 66,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
| Media: | |
| Ambre James-Brown +45 3079 9289 abmo@novonordisk.com | Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com |
| Investors: | |
| Daniel Muusmann Bohsen +45 3075 2175 dabo@novonordisk.com | Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com |
| David Heiberg Landsted +45 3077 6915 dhel@novonordisk.com | Mark Joseph Root (US) +1 848 213 3219 mjhr@novonordisk.com |
| Sina Meyer +45 3079 6656 azey@novonordisk.com | Frederik Taylor Pitter +45 3075 8259 fptr@novonordisk.com |
| Ida Melvold Gjøsund +45 3077 5649 idmg@novonordisk.com |
Company announcement No 39 / 2024
Attachment
